At Worldwide Clinical Trials, we are committed to advancing science by ensuring that clinical research reflects a diverse range of patient populations, demographics, and co-morbidities. We believe that this representation is crucial for developing treatments that are effective and accessible to everyone
We offer comprehensive solutions across clinical program development, regulatory strategy, diversity action planning, and operational solutions in trial delivery.
Global regulatory agencies are emphasizing the importance of how different populations respond to treatment. Health authorities in various regions now expect drug developers to have formal Diversity Action Plans in place during the clinical development process – typically requiring these to be available by phase III but to consider starting earlier to benefit from aggregated data across a development program. Implementing a formal Diversity Action Plan brings several strategic advantages to your drug development program, such as:
Worldwide offers practical knowledge in global regulatory environments through all phases of the drug development process. Additionally, we provide extensive industry experience shaping project plans to ensure clinical data is representative of patient populations, further enforcing scientific validity and generalizability. Our approach includes:
At Worldwide, we implement a personalized operational approach with experts from all functional areas of project delivery.